http://www.raqualia.com/

NEWS RELEASE

RaQualia Receives a Patent Allowance for 5-HT_{2B} Antagonist in China

June 1, 2015 - RaQualia Pharma Inc. (RaQualia) today announced that the company received an allowance* for a 5-HT_{2B} antagonist substance patent in China (Application number: 200980146558.8). In addition to the patents previously granted in Japan, the U.S.A. and Europe, this allowance ensures that the company's intellectual property rights will be strengthened in China.

5-HT_{2B} receptors are widely expressed throughout human intestinal tracts, and experimental evidence suggests that these receptors play a key role in mediating gastrointestinal motility and visceral perception. In animal models, the 5-HT_{2B} antagonist (RQ-00310941) attenuated visceral hypersensitivity and inhibited abnormal defecation. Therefore, RQ-00310941 may be useful in the relief of symptoms (abdominal pain or discomfort, and abnormal bowel movements) associated with lower gastrointestinal diseases. RQ-00310941 is in the run-up to a Phase I clinical trial in the United Kingdom.

RaQualia will continue to focus on obtaining patents for the 5-HT_{2B} antagonist in other regions and promote licensing activities globally.

The financial forecasts for FY 2015 issued on May 14, 2015, will not be affected by this announcement.

*A patent allowance is an evaluation by a country's patent office that a patent application merits being granted a patent. After the patent is allowed and the fee paid, it is registered and the patent is issued in the relevant country.

Contact:
E-mail address: ir@raqualia.com
URL: www.raqualia.com

####